The advance could eventually give nanopore sequencing an advantage over current methods for identifying methylation sites, such as bisulfite sequencing, because the DNA would not first have to be modified or amplified.
Under the new agreement, which has an undisclosed duration, the company will provide an undisclosed amount of funding to support research in Hagan Bayley's group and will partner exclusively with the university to develop "revolutionary products for molecular analysis" based on discoveries made by the group.
The company will partner exclusively with Oxford University to develop "revolutionary products" for molecular analysis from research done in Bayley's lab, including the development of methods for the direct sequencing of single-stranded DNA.
British and French researchers reported today that they have investigated ties between more than a dozen previously detected, low penetrance risk variants and the risk of developing breast cancer and sub-types of the disease.
After looking for associations between common CNVs and eight common diseases in more than 16,000 affected individuals, members of the Wellcome Trust Case Control Consortium concluded that these CNVs aren't major players in these diseases.
A co-author of the study said that "the presence or absence of the biomarker can now be used as a diagnostic test to identify which patients will benefit from this drug," and added that their approach can be used to screen the efficacy of any drug for any disease.
Sequenom also said that it amended its license with Isis Innovation for IP underlying its SEQureDx Down syndrome test, which the firm continues to develop following an investigation into mishandled R&D test data and results.